Headline
The latest stories from AHA Today.
The Food and Drug Administration yesterday approved for emergency use a ventilator specially developed by the National Aeronautics and Space Administration to treat COVID-19 patients.
The Department of Health and Human Services, through its Health Resources and Services Administration, awarded $20 million to increase capability, capacity and access to telehealth and distant care services for providers, pregnant women, children, adolescents and families.
Participating today in a virtual event on the COVID-19 pandemic, AHA President and CEO Rick Pollack talked with David Rubenstein, president of The Economic Club of Washington, D.C., about the financial challenges hospitals face.
The Centers for Medicare & Medicaid Services released a number of new waivers related to COVID-19. The waivers apply nationwide and are generally retroactive to March 1, 2020.
A new resource from AHA helps hospitals and health systems think through in under an hour how to partner with other organizations to meet their needs during the pandemic.
On this AHA Advancing Health podcast, Darren Henson, director of operations at AHA’s Institute for Diversity and Health Equity, talks with Lena Hatchett, professor at the Loyola University Chicago Stritch School of Medicine, about how despite the COVID-19 outbreak, her facility remains committed to…
The Economic Club of Washington, D.C., which provides a forum for business issues confronting the nation and world, tomorrow will host a virtual event to gather insights from AHA President and CEO Rick Pollack and other leaders on their response to the COVID-19 pandemic.
The Food and Drug Administration issued an emergency use authorization for Abbott Laboratory’s SARS-CoV-2 IgG assay for the qualitative detection of COVID-19 antibodies.
Researchers at the National Institute of Mental Health are conducting an online study to learn how stressors related to the COVID-19 virus affect the mental health of health care workers over time.
A trial sponsored by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases provided preliminary indications that hospitalized patients with advanced COVID-19 and lung involvement who received remdesivir recovered faster than similar patients who received a…